Benign prostatic hypertrophy
Conditions
Interventions
intake of tolvaptan 7.5mg as a preoperative medication
intake of tolvaptan 7.5mg as a preoperative medication
no intake of tolvaptan as conventional treatment
Sponsors
Osaka Medical College
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Benign prostatic hypertrophy 2) male: 20-89 year-old 3) patients showed consent of this study
Exclusion criteria
Exclusion criteria: 1) emergency operation 2) simultaneously having different operation 3) serum potassium level <125mmol/l 4) having severe coronary diseases and cerebral vessel diseases 5) having severe liver dysfunctions 6) hyperkalemia 7) hemodialysis 8) permanent pacemaker 9) medication of CYP3A4 inhibitors 10) medication of vasopression related drugs 11) medication of inotropic agents 12) medication of Potassium-sparing diuretics 13) BMI>or=35 14) Coagulation disorder 15) Severe complication with a diagnosis of 6 months remaining 16) Participation in other intervention studies 17) being judged as not appropriate for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change of serum potassium levels and occurrence of TUR syndrome | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) perioperative mortality 2) neurological and circuratory abnormality 3) serum creatinine levels 4) lactate levels | — |
Countries
Japan
Contacts
Public ContactJunko Nakahira
Osaka Medical College Department of Anesthesiology
Outcome results
None listed